摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-(3-Fluoro-phenyl)-5-isopropyl-2H-pyrazol-3-yl]-3-[3-(1-methyl-1H-pyrazolo[3,4-c]pyridin-4-ylethynyl)-phenyl]-urea | 1160243-74-2

中文名称
——
中文别名
——
英文名称
1-[2-(3-Fluoro-phenyl)-5-isopropyl-2H-pyrazol-3-yl]-3-[3-(1-methyl-1H-pyrazolo[3,4-c]pyridin-4-ylethynyl)-phenyl]-urea
英文别名
1-[2-(3-Fluorophenyl)-5-propan-2-ylpyrazol-3-yl]-3-[3-[2-(1-methylpyrazolo[3,4-c]pyridin-4-yl)ethynyl]phenyl]urea
1-[2-(3-Fluoro-phenyl)-5-isopropyl-2H-pyrazol-3-yl]-3-[3-(1-methyl-1H-pyrazolo[3,4-c]pyridin-4-ylethynyl)-phenyl]-urea化学式
CAS
1160243-74-2
化学式
C28H24FN7O
mdl
——
分子量
493.543
InChiKey
DZICJQXMJAIHHH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    37
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    89.7
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    3-((1-methyl-1H-pyrazolo[3,4-c]pyridin-4-yl)ethynyl)-phenylamine 、 [2-(3-fluoro-phenyl)-5-isopropyl-2H-pyrazol-3-yl]-carbamic acid phenyl ester 在 吡啶 作用下, 以 四氢呋喃 为溶剂, 反应 0.25h, 生成 1-[2-(3-Fluoro-phenyl)-5-isopropyl-2H-pyrazol-3-yl]-3-[3-(1-methyl-1H-pyrazolo[3,4-c]pyridin-4-ylethynyl)-phenyl]-urea
    参考文献:
    名称:
    Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
    摘要:
    该发明涉及通式(I)所示的炔基芳基化合物:其中A、B、D、E、Ra、R1、R3、R4、R5和q如权利要求中所定义,并且其盐、N-氧化物、溶剂合物和前药,包括所述炔基芳基化合物的药物组合物,制备所述炔基芳基化合物的方法,用于所述方法的有用中间化合物,以及用于所述中间化合物在制备所述炔基芳基化合物时的用途,以及用于制备治疗失调血管生长疾病或伴随失调血管生长的疾病的药物组合物的所述炔基芳基化合物的用途。
    公开号:
    EP2070929A1
点击查看最新优质反应信息

文献信息

  • ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
    申请人:Hartung Ingo
    公开号:US20100261730A1
    公开(公告)日:2010-10-14
    The invention relates to alkynylaryl compounds according to the general formula (I) in which A, B, D, E, R a , R 1 , R 3 , R 4 , R 5 and q are as defined in the claims, and salts, N-oxides, solvates and prodrugs thereof, to pharmaceutical compositions comprising said alkynylaryl compounds, to methods of preparing said alkynylaryl compounds, to intermediate compounds useful in said methods, to uses of said intermediate compounds in the preparation of said alkynylaryl compounds, as well as to uses of said alkynylaryl compounds for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth.
    本发明涉及通式(I)的炔基芳基化合物,其中A、B、D、E、Ra、R1、R3、R4、R5和q如权利要求所定义的,以及其盐、N-氧化物、溶剂合物和前药,包括含有该炔基芳基化合物的制药组合物,制备该炔基芳基化合物的方法,用于该方法的中间体化合物,以及用于制备治疗失调血管生长疾病或伴随失调血管生长的疾病的制药组合物的该炔基芳基化合物的用途。
  • JP2011506365A
    申请人:——
    公开号:JP2011506365A
    公开(公告)日:2011-03-03
  • US8481539B2
    申请人:——
    公开号:US8481539B2
    公开(公告)日:2013-07-09
  • [EN] ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME<br/>[FR] COMPOSÉS D'ALCYNYLARYLE ET LEURS SELS, COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
    申请人:BAYER SCHERING PHARMA AG
    公开号:WO2009074260A1
    公开(公告)日:2009-06-18
    The invention relates to alkynylaryl compounds according to the general formula (I) in which A, B, D, E, Ra, R1, R3, R4, R5 and q are as defined in the claims, and salts, N-oxides, solvates and prodrugs thereof, to pharmaceutical compositions comprising said alkynylaryl compounds, to methods of preparing said alkynylaryl compounds, to intermediate compounds useful in said methods, to uses of said intermediate compounds in the preparation of said alkynylaryl compounds, as well as to uses of said alkynylaryl compounds for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth.
  • Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
    申请人:Bayer Schering Pharma Aktiengesellschaft
    公开号:EP2070929A1
    公开(公告)日:2009-06-17
    The invention relates to alkynylaryl compounds according to the general formula (I) : in which A, B, D, E, Ra, R1, R3, R4, R5 and q are as defined in the claims, and salts, N-oxides, solvates and prodrugs thereof, to pharmaceutical compositions comprising said alkynylaryl compounds, to methods of preparing said alkynylaryl compounds, to intermediate compounds useful in said methods, to uses of said intermediate compounds in the preparation of said alkynylaryl compounds, as well as to uses of said alkynylaryl compounds for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth.
    该发明涉及通式(I)所示的炔基芳基化合物:其中A、B、D、E、Ra、R1、R3、R4、R5和q如权利要求中所定义,并且其盐、N-氧化物、溶剂合物和前药,包括所述炔基芳基化合物的药物组合物,制备所述炔基芳基化合物的方法,用于所述方法的有用中间化合物,以及用于所述中间化合物在制备所述炔基芳基化合物时的用途,以及用于制备治疗失调血管生长疾病或伴随失调血管生长的疾病的药物组合物的所述炔基芳基化合物的用途。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺